LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.25M | -3.95M | -2.03M | 1.97M | 2.54M |
| Total Depreciation and Amortization | 2.31M | 2.07M | 1.81M | 1.62M | 1.44M |
| Total Amortization of Deferred Charges | 4.30K | 4.30K | 4.30K | -- | -- |
| Total Other Non-Cash Items | 1.34M | 1.03M | 950.90K | -846.50K | -1.71M |
| Change in Net Operating Assets | -2.68M | -3.14M | -2.51M | -4.89M | -1.27M |
| Cash from Operations | -4.26M | -3.98M | -1.77M | -2.15M | 997.40K |
| Capital Expenditure | -1.33M | -1.37M | -1.45M | -430.60K | -691.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.79M | -1.79M | -1.79M | -800.10K | -822.10K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.61M | -2.36M | -2.11M | -2.59M | -2.19M |
| Cash from Investing | -5.74M | -5.52M | -5.36M | -3.82M | -3.70M |
| Total Debt Issued | 24.69M | 28.58M | 24.73M | 22.33M | 15.64M |
| Total Debt Repaid | -13.34M | -13.39M | -13.32M | -13.22M | -5.92M |
| Issuance of Common Stock | 2.32M | 2.32M | 2.32M | 2.28M | 960.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.82M | -3.75M | -3.57M | -2.82M | -2.21M |
| Cash from Financing | 7.09M | 9.91M | 7.30M | 6.16M | 6.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.91M | 410.30K | 169.90K | 193.20K | 3.38M |